Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.

Dr Suchitra Sundaram reflects on time limited venetoclax combinations, next generation non covalent BTK inhibitors, and novel ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...

Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and ...

The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

Healio spoke with Matthew S. Davids, MD, about a recent study comparing continuous treatment with a Bruton tyrosine kinase inhibitor with time-limited venetoclax-based therapy for chronic lymphocytic ...